

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Provisional Application NoStamps

60/032.414

December 5, 1996

Pending

Application Serial No

Status

N/A

and each of them, all c/o Cooper & Dunham LLP, 1105 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone calls, regarding this application to:

John P. White Reg. No. 28,678
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor Don Fishbein

Inventor's signature Don Fishbein

Citizenship United States Date of signature June 17, 1998

Residence 314 Scotch Plain, Westfield, New Jersey 07090

Post Office Address same as residence address

Applicant BTG (0336) 19036 JPW/GJG
Client January 14, 2004 File No. Atty.
Date

Kindly acknowledge receipt of the accompanying

FORM PTO 1595 (Substitute) Requesting Change of Name of Assignee Bio-Technology General Corp. to SAVIENT PHARMACEUTICALS, INC. in connection with 42 U.S. Patents and 7 pending U.S. applications as listed in the attachment (2 pages) to Form PTO-1595 (Substitute), including a copy of the Certificate of Amendment of Certificate of Incorporation of Bio-Technology General Corp., and Certificate of Mailing dated January 14, 2004.

by placing your receiving date stamp hereon and returning to us.

Applicant BTG (0336) 19036 JPW/GJG
Client January 14, 2004 File No. Atty.
Date

Kindly acknowledge receipt of the accompanying

FORM PTO 1595 (Substitute) Requesting Change of Name of Assignee Bio-Technology General Corp. to SAVIENT PHARMACEUTICALS, INC. in connection with 42 U.S. Patents and 7 pending U.S. applications as listed in the attachment (2 pages) to Form PTO-1595 (Substitute), including a copy of the Certificate of Amendment of Certificate of Incorporation of Bio-Technology General Corp., and Certificate of Mailing dated January 14, 2004.

by placing your receiving date stamp hereon and returning to us.

To the Honorable Commissioner of Patents and Trademarks. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Bio-Technology General Corp.

Additional name(s) of conveying party(ies) attached?

☐ Yes ☒ No

3. Nature of Conveyance:

- ☐ Assignment ☐ Merger
☐ Security Agreement ☒ Change of Name
☐ Other _____

Execution Date(s): June 23, 2003

2. Name and address of receiving party(ies):

Name: Savient Pharmaceuticals, Inc.

Internal Address: 14th Floor

Street Address: One Tower Center Boulevard

City/State/Zip: East Brunswick, NJ 08816

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date(s) of the application is(are): _____

A. Patent Application No.(s) _____
SEE ATTACHMENT

B. Patent No.(s) _____
SEE ATTACHMENT

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: John P. White

Internal Address: Cooper & Dunham LLP

Street Address: 1185 Avenue of the Americas

City/State/Zip: New York, New York 10036

6. Total number of applications and patents involved: 49

7. Total fee (37 CFR §3.41): \$ 1,960.00

☐ Enclosed

☒ Authorized to be charged to deposit account

8. Deposit account number:

03-3125

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

John P. White
Name of Person Signing

John P. White
Signature
Reg. No. 28,678

January 14, 2004
Date

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

John P. White
John P. White
Reg. No. 28,678

1/14/04

Date

Total Number of pages including cover sheet, attachments and document: 6

Page 1 of 3
Continuation of Box 4 of Form PTO-1595 (Substitute)
(recording name change from Bio-Technology General Corp.
TO
Savient Pharmaceuticals, Inc.)

Application No.	Application Date	Patent No.	Issue Date
06/752,441	July 3, 1985	4,831,120	May 16, 1989
07/320,320	March 7, 1989	4,997,916	March 5, 1991
07/539,367	June 15, 1990	5,112,744	May 12, 1992
07/692,630	April 29, 1991	5,116,616	May 26, 1992
07/317,434	March 1, 1989	5,126,252	June 30, 1992
07/194,424	May 13, 1988	5,143,836	September 1, 1992
07/780,353	October 22, 1991	5,147,789	September 15, 1992
07/822,054	January 14, 1992	5,151,364	September 29, 1992
07/449,125	December 8, 1989	5,162,217	November 10, 1992
07/635,413	January 3, 1991	5,198,361	March 30, 1993
07/790,485	November 12, 1991	5,242,812	September 7, 1993
07/842,740	February 27, 1992	5,246,847	September 21, 1993
07/840,578	February 24, 1992	5,256,546	October 26, 1993
07/526,397	May 21, 1990	5,270,030	December 14, 1993
07/912,213	July 10, 1992	5,270,195	December 14, 1993
08/029,030	March 10, 1993	5,360,729	November 14, 1994
08/058,241	May 4, 1993	5,455,158	October 3, 1995
08/370,461	January 9, 1995	5,540,911	July 30, 1996
08/261,750	June 17, 1994	5,593,860	January 14, 1997
08/340,045	November 14, 1994	5,637,495	June 10, 1997
08/459,356	July 2, 1995	5,670,371	September 23, 1997
08/259,569	June 14, 1994	5,679,320	October 21, 1997
08/450,014	May 25, 1995	5,759,816	June 2, 1998
08/400,544	March 8, 1995	5,763,215	June 9, 1998

Page 2 of 3
Continuation of Box 4 of Form PTO-1595 (Substitute)
(recording name change from Bio-Technology General Corp.
TO
Savient Pharmaceuticals, Inc.)

08/216,851	March 22, 1994	5,795,776	August 18, 1998
08/826,885	April 8, 1997	5,869,616	February 9, 1999
08/986,015	December 5, 1997	5,872,147	February 16, 1999
08/897,043	July 18, 1997	5,945,304	August 31, 1999
08/782,760	January 13, 1997	5,948,668	September 7, 1999
08/409,750	March 24, 1995	5,965,383	October 12, 1999
08/267,867	November 12, 1997	6,001,604	December 14, 1999
08/686,465	July 25, 1996	6,010,875	January 4, 2000
08/451,474	May 26, 1995	6,030,611	February 29, 2000
08/871,302	June 9, 1997	6,054,291	April 25, 2000
08/244,988	October 20, 1993	6,090,799	July 18, 2000
08/909,140	August 11, 1997	6,121,426	September 19, 2000
08/686,466	July 25, 1996	6,361,772	March 26, 2002
08/985,734	December 5, 1997	6,576,659	June 10, 2003
08/299,047	August 31, 1994	6,610,520	August 26, 2003
09/469,817	December 22, 1999	6,670,351	December 30, 2003
08/369,309	January 6, 1995	RE35724	February 3, 1998
29/040,830	June 28, 1995	Des. 403064	December 22, 1998

Page 3 of 3
Continuation of Box 4 of Form PTO-1595 (Substitute)
(recording name change from Bio-Technology General Corp.
TO
Savient Pharmaceuticals, Inc.)

Application No.	Application Date	Patent No.	Issued
08/023,248	February 13, 1998		
07/188,303	April 29, 1988		
09/492,971	January 27, 2000		
09/469,817	December 22, 1999		
10/052,961	January 16, 2002		
09/390,225	September 3, 1999		
10/011,377	October 22, 2001		


Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "BIO-TECHNOLOGY GENERAL CORP.", CHANGING ITS NAME FROM "BIO-TECHNOLOGY GENERAL CORP." TO "SAVIENT PHARMACEUTICALS, INC.", FILED IN THIS OFFICE ON THE TWENTY-FOURTH DAY OF JUNE, A.D. 2003, AT 9:30 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE
NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

0894913 8100

030416268

AUTHENTICATION: 2515430

DATE: 07-08-03

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
OF
BIO-TECHNOLOGY GENERAL CORP.

Bio-Technology General Corp., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, (the "Corporation"), DOES HEREBY CERTIFY:

FIRST: Articles FIRST and SECOND of the Certificate of Incorporation of the Corporation is hereby amended and replaced in its entirety with the following:

"FIRST: The name of the corporation is Savient Pharmaceuticals, Inc. (hereinafter referred to as the "Corporation").

SECOND: The address of the Corporation's registered office in Delaware is Corporation Trust Center, 1209 Orange Street, City of Wilmington, 19801, County of New Castle. The name of its registered agent at such address is The Corporation Trust Company."


SECOND: The Certificate of Amendment of Certificate of Incorporation herein certified was duly adopted in accordance with the applicable provisions of Section 242 of the General Corporation Law of the State of Delaware.


THIRD: The Certificate of Amendment herein certified was duly adopted at the annual meeting of the stockholders of the Corporation duly called and held, upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware, at which meeting the necessary number of shares as required by statute voted in favor of the amendment to the Corporation's Certificate of Incorporation.

IN WITNESS WHEREOF, the undersigned has caused this Certificate of Amendment of Certificate of Incorporation to be signed, under penalties of perjury, and the facts stated herein are true and correct.

Dated: June 23, 2003

SAVIENT PHARMACEUTICALS, INC.

By: 
Name: Robert M. Shaw
Title: Executive Vice President and
Chief Administrative Officer


Rhonda De Stefano, Esq.

NAME CHANGE

From:
Bio-Technology General Corp.
TO
Savien: Pharmaceuticals, Inc.

Attorney for

John P. White
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, N.Y. 10036
212-278-0400

Assignment

In consideration of One Dollar (\$1.00), and other good and valuable considerations, the receipt of which is hereby acknowledged, I, the undersigned, Don Fishbein, residing at 314 Scotch Plain, Westfield, New Jersey 07090

Hereby sell, assign and transfer to Bio-Technology General Corp.

a corporation of the State of

Delaware having a place of business at 70 Wood Avenue South, Metro Park Financial Center in the County of Middlesex and State of New Jersey 08830 its successors, assigns and legal representatives, the entire right, title and interest for all countries, in and to any and all inventions which are disclosed and claimed, and any and all inventions which are disclosed but not claimed, in the application for United States Patent, which has been executed by the undersigned on June 17, 1998 and is entitled

THE USE OF OXANDROLONE IN THE TREATMENT OF BURNS AND OTHER WOUNDS
(U.S. Serial No. 08/985,734, filed December 5, 1997, claiming priority
of U.S. Provisional Application No. 60/032,414, filed December 5, 1996)

and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other applications for U.S. Letters Patent or other related property rights in any and all foreign countries which have been or shall be filed on any of said inventions disclosed in said application; and in and to all original and reissued patents or related foreign documents which have been or shall be issued on said inventions;

Authorize and request the Commissioner of Patents of the United States to issue to said Assignee, the corporation above named, their successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said inventions or any of them disclosed in said application;

Agree that said Assignee may apply for and receive foreign Letters Patent or rights of any other kind for said inventions, or any of them; and may claim, in applications for said foreign Letters Patent or other rights, the priority of the aforesaid United States patent application under the provisions of the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty, under the European Patent Convention or under any other available international agreement; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned or the undersigned's executors or administrators will, for the United States and all foreign countries, execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications or other documents on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns and representatives, all facts known and documents available to the undersigned relating to said inventions and the history thereof; testify in all legal proceedings; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said Assignee, its successors, assigns and legal representatives; and

Covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

Date: June 17, 1998 19

Witness: Sabin G. Breen

Julia Mc Breen

9 Iona Place

Aberdeen, NJ 07747

Don Fishbein

Don Fishbein

[L.S.]